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Purpose or Objective 
Adjuvant radiotherapy for breast cancer treatment has 
been long shown to reduce the risk of recurrence, but also 
results in incidental exposure of organs at risk (OAR) such 
as the heart and lungs. Several studies have reported on 
cardiac toxicity, showing an increase in the rate of 
ischemic heart disease after radiotherapy for left-sided 
breast cancer; and meta-analyses of women treated with 
breast radiotherapy have shown an increased risk of 
primary lung cancer, which is even more appreciable in 
the smoking population. Other potential lung 
complications from breast radiotherapy include 
pneumonitis and subsequent fibrosis, the risk of which 
further increases with the addition of chemotherapy. In 
this retrospective dosimetric study, we report on the 
cardiac and lung doses from over 400 breast cancer 
patients treated with radiotherapy at our centre, with the 
long-term goal of correlating dose to toxicity. 
Material and Methods 
412 breast cancer patients treated with 50Gy in 25 
fractions or 42.56Gy in 16 fractions were identified 
retrospectively. Cohorts were stratified based on the 
radiation technique including (i) 2-field tangential beam 
arrangement (n=256) (ii) 3- and 4-field techniques with 
standard tangents (n=92) and (iii) 4-field technique with 
wide tangents (n=64) to include the internal mammary 
chain (IMC), which was further stratified between 
treatment of right (n=34) and left-sided disease (n=30). Of 
the latter, patients simulated in free-breathing (n=8) and 
those simulated with a modified deep inspiration breath-
hold technique (mDIBH) (n=22) were analysed separately. 
Standardized contouring based on the RTOG breast cancer 
atlas, in combination with standard field based planning 
was used.  Dosimetric heart parameters evaluated 
included mean heart dose (MHD) and V(50%). Metrics for 
the combined lung volumes included V5Gy, V20Gy and 
Mean Lung Dose (MLD). ANOVA was also used to compare 
the dose between the techniques for statistical 
significance. 
Results 
Dosimetric parameters for heart and lung are reported in 
table 1 for the different techniques, with the differences 
shown to be statistically significant. Breast cancer 
patients treated with radiotherapy which included 
regional nodal irradiation increased dose to both heart and 
lungs. mDIBH significantly reduced the dose to the heart 
as compared to the free-breathing technique. 
 
 
 
Conclusion 
Standardized contouring and planning facilitates a 
meaningful dosimetric evaluation of OAR dose associated 
with breast radiotherapy, which in future studies can be 
correlated with toxicity.  In an era where the benefits of 
breast radiotherapy well outweigh the risks in the majority 
of patients, it is important to consider the potential long-
term effects of breast cancer radiotherapy from a 
survivorship lens. 
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Purpose or Objective 
OncotypeDX can enhance prediction of breast cancer 
recurrence (BRC), guiding adjuvant treatment options. 
Many studies showed a low local relapse for Recurrence 
Score (RS) < 18 and probably in these patients would be 
possible to deescalate adjuvant radiotherapy (RT). 
However, the opportunity to access this test is not always 
possible. The aim of this study is to investigate the 
correlation between classical immunohistochemistry (IHC) 
and RS in order to offer to clinicians a Decision Supporting 
System to be validated for deescalating RT 
Material and Methods 
All patients who for ER+ HER2- breast cancer underwent 
Oncotype between 2014 and 2018 were retrospectively 
included in the study. The data selected for analysis were: 
age, menopausal status, pT, pN, PVI, IHC, RS and ER, PgR 
and HER2 expressed on Oncotype analysis. IHC was 
performed with standardized semi-quantitative method. 
Multivariable logistic regression analyses were applied to 
ascertain the associations between all these parameters 
and RS 
Results 
The study comprised 407 patients who underwent 
Oncotype. Mean age was 53.7 (31-80) and 222 pts (54.55%) 
were > 50 years old. Oncotype results showed: 67 pts 
(16.5%) between 0-10, 173 pts between 11 and 18 (42.5%), 
133 pts between 19 and 30 (32.7%), and 34 pts > 30 (8.3%). 
At the logistic regression analysis, RS score was 
significantly associated with ER (p=0.004), PgR 
(p<0.0001), and Ki67% (p<0.0001). Above pts with 
Oncotype ≤18 (0-18), a linear regression showed a model 
with AUC 0.814 (sensitivity 75%; specificity 75%) (Figure 
1). Ten-cross fold validation of the model presented a 
mean AUC of 0,80 (0.7-0.9). A nomogram was generated 
for further prospective evaluation, predicting RS score < 
18 for internal IHC prognostic factor (Figure 2). 
Conclusion 
Prognostic factors present a good correlation with RS score 
in pts with RS ≤ 18 in our series. A nomogram for physician 
that enhance a good cost/effectiveness clinical practice 
need to be tested prospectively for deescalating adjuvant 
RT 
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Purpose or Objective 
To compare the clinically achieved dosimetry of ACCEL 
trial with the trial’s rigorous dosimetry guidelines in 
context with phase III multi-institutional accelerated 
partial breast irradiation (APBI) trials. These dosimetry 
guidelines were significantly stricter than dosimetry 
constraints formally imposed by trial protocol.  
Material and Methods  
The ACCEL trial (https://clinicaltrials.gov/NCT02681107) 
is a Canadian, multi-institutional, phase II prospective 
